Search

Your search keyword '"Svicher, V."' showing total 384 results

Search Constraints

Start Over You searched for: Author "Svicher, V." Remove constraint Author: "Svicher, V."
384 results on '"Svicher, V."'

Search Results

2. Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies

3. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper

4. HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV sub-genotypes 1 inducing different inflammatory stimuli

5. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro

6. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

7. Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure

10. An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein

18. for the Icona Foundation Study Group Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays

23. Evaluation of HIV transmission clusters among natives and foreigners living in Italy

26. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group

27. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

29. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor

30. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia

31. HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients

33. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

38. The combined usage of accurate virological and serological HBV markers can help to identify HBsAg-negative/anti-HBc-positive patients at higher risk of HBV-reactivation and to optimize prophylaxis duration in oncohematological setting

39. Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression

40. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

42. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

43. Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?

44. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

45. A close monitoring of virological and immunological hepatitis B markers can improve the diagnosis of HBV reactivation in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases

46. The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative chronic infection: implications for an altered cell homeostasis and metabolism

47. Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection

49. Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: an extensive analysis of HBV genome

50. A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection

Catalog

Books, media, physical & digital resources